Radius Health, Inc . RDUS is a Waltham, Massachusetts-based development-stage biopharmaceutical company with a focus on the development of new therapeutics for the treatment of osteoporosis and other serious endocrine-mediated diseases.
With no approved products in its portfolio, Radius Health has not generated revenues yet. In this scenario, investor focus remains on updates on pipeline progress.
Candidates in the company's pipeline include the subcutaneous formulation and transdermal patch of abaloparatide, and RAD1901. The company has filed for an approval of its lead candidate, abaloparatide (postmenopausal osteoporosis and reduction of fracture risk), in the EU, which is currently under review. The company expects an opinion from the Committee for Medicinal Products for Human Use (CHMP) for its application later in 2016. Radius Health also submitted a New Drug Application (NDA) in the U.S. for abaloparatide-SC at the end of the first quarter of 2016, after a quarter's delay. A potential approval would allow Radius Health to record its first commercial sales in 2016.
Currently, Radius Health has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings : Radius Health posted wider-than-expected loss in the first quarter of 2016. While our consensus called for a loss of 83 cents per share, the company reported a loss of 94 cents.
Revenue : With no approved product in its portfolio, Radius Health has not generated any revenues in the reported quarter.
Key Stats : Radius Health is currently seeking a commercialization partner for abaloparatide-SC prior to launch. Radius Health is also developing abaloparatide-transdermal, (abaloparatide-TD) as a short wear-time transdermal patch. In Dec 2015, the company initiated a human replicative clinical evaluation to compare the optimized abaloparatide-TD patch with the subcutaneous formulation and expects to update on the study in mid-2016.
Check back for our full write up on earnings report later!